Fast-track your Precision Medicine R&D programs with Syngene
Book a meeting now to discuss how Syngene can assist you in advancing your research programs in Precision Medicine.
Precision Medicines promise to provide treatments that suit specific patient populations, rather than a one-size-fits-all approach where treatments are developed with little consideration for differences between individuals. Syngene has built considerable expertise in Precision Medicines in recent years, working with both large pharma clients as well as helping new biotechs rapidly scale their programs.
Book a virtual meeting
Syngene’s capability lies in two key areas –– Molecularly Targeted Therapy and Immunotherapy. We have a comprehensive suite of services across NGS, cell Line engineering (CRISPR-Cas9), CAR-T proof of principle studies (autologous and allogeneic) and In-vivo oncology models (PDX/CDX/Syngeneic/Humanized). Syngene also offers extensive services across customized reagent generation, antibody development [monoclonal / bispecific/ trispecific/ antibody-drug conjugates (ADCs)], cell line development and In-vivo PK studies.
Syngene’s rich suite of Precision Medicine capabilities
Play Video
Play Video
Novel bi-specific antibody approach published in Leukemia
Our expertise in Precision Oncology research was covered in Leukemia, a leading medical journal from Nature. Our paper discusses a novel bi-specific antibody approach to acute myeloid leukemia (AML), the entire work for which was done at Syngene. Read here.
360-degree virtual facilities tour
You can now take a full 360-degree virtual tour of our facilities that enable our advanced Precision Medicine services. Start your tour now.
Syngene International Limited
All rights reserved © 2023